Skip to Main Content

Advertisement

Skip Nav Destination

Season 1, Episode 47

In this week’s episode, we will review an proof-of concept study using the bispecific antibody AFM13 in combination with a check-point inhibitor in patients with relapsed or refractory Hodgkin lymphoma, learn more about how iron restriction might be a promising new therapy for congenital erythropoietic porphyria, and review a manuscript that provides novel molecular insights into the requirement for RUNX1 in a mouse model of inversion 16 acute myeloid leukemia, providing a path forward for new therapies to treat this subgroup of AML.

Released November 19, 2020

The articles highlighted in this episode are listed below:


Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X